protein kinase C theta (Rigel Pharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameprotein kinase C theta (Rigel Pharmaceuticals)
Drug Alias NameR-683R-687
ClassificationSmall molecules
Mechanisms of ActionProtein kinase C theta inhibitors
TargetsProtein kinase C theta
Therapy Area/IndicationsInflammationAutoimmune DiseasesNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A